【摘要】 目的 评价载药微球支气管动脉化疗栓塞术(DEBBACE)续贯放化疗治疗非小细胞肺癌(NSCLC)的疗效和安全性。方法 回顾性分析采用首治DEBBACE再续贯放化疗方案的12例NSCLC患者的临床资料。结果 12例患者随访时间7～24个月，平均16个月，首次DEBBACE术后第1、3、6个月客观缓解率(ORR)达到100%、91.7%、91.7%;疾病控制率(DCR)达到100%、100%、91.7%,无进展生存期(PFS)为8个月(6～12月),总生存期(OS)>24个月。最常见的不良事件为恶心、呕吐、咳嗽咳痰、胸骨后疼痛等栓塞后栓塞征(n=10),可自行消失。2例出现广泛肺部感染，经抗感染治疗后恢复，所有患者未出现介入栓塞相关的严重并发症。结论 首治DEBBACE+续贯放化疗方案对晚期NSCLC疗效良好，具有较高的安全性。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization(DEB-BACE)and sequential chemoradiotherapy for the treatment of non-small cell lung cancer(NSCLC). Methods The clinical data of 12 patients with NSCLC who were treated with DEB-BACE first and followed by selquential chemoradiotherapy were analyzed retrospectively. Results The average follow-up time of 12 patients was 16 months(7-24 months).The objective response rate(ORR)and disease control rate(DCR) were 100%,91.7%,91.7% and 100%,100%,91.7% respectively at 1, 3,and 6 months after DEB-BACE.The progress-free survival(PFS)was 8 months(6-12 months),and the overall survival(OS) was more than 24 months.The most common adverse event was the postembolization syndrome including nausea, vomiting, cough, expectoration, and pain behind the sternum(n=10),while the symptoms would clear up of their own accord. Two patients developed extensive pulmonary infection, then recovered after antibiotic treatment. No embolization-related serious adverse reactions occurred in all patients. Conclusion The first DEB-BACE followed by sequential chemoradiotherapy for the treatment of advanced NSCLC has excellent curative effect and higher safety.更多还原